Hubbry Logo
SynucleinopathySynucleinopathyMain
Open search
Synucleinopathy
Community hub
Synucleinopathy
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Synucleinopathy
Synucleinopathy
Synucleinopathy
View on Wikipedia
from Wikipedia
Synucleinopathy
Other namesα-synucleinopathies
Positive α-synuclein staining (brown) of a Lewy body in the substantia nigra of an individual with Parkinson's disease
SpecialtyNeurology
SymptomsAutonomic dysfunction, motor impairments, cognitive and sleep issues, parkinsonism, memory loss, hallucinations
DurationLong term
TypesParkinson's disease, dementia with Lewy bodies, multiple system atrophy
CausesUnknown

Synucleinopathies are neurodegenerative diseases characterised by the abnormal accumulation of aggregates of alpha-synuclein protein in neurons, nerve fibres or glial cells.[1] The synucleinopathies include Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA).[1] Other rare disorders, such as various neuroaxonal dystrophies, also have α-synuclein pathologies.[2]

Classification

[edit]

The synucleinopathies include Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA).[1] Other rare disorders, such as various neuroaxonal dystrophies, also have α-synuclein pathologies.[2]

Signs and symptoms

[edit]

The synucleinopathies have shared features of parkinsonism, impaired cognition, sleep disorders, and visual hallucinations.[3]

Synucleinopathies can overlap with tauopathies, possibly because of interaction between the synuclein and tau proteins.[4]

REM sleep behavior disorder (RBD) is a parasomnia in which individuals with RBD lose the paralysis of muscles (atonia) that is normal during rapid eye movement (REM) sleep, and act out their dreams or have other abnormal movements or vocalizations.[5] Abnormal sleep behaviors may appear decades before any other symptoms, often as an early sign of a synucleinopathy.[6] On autopsy, 94 to 98% of individuals with polysomnography-confirmed RBD are found to have a synucleinopathy—most commonly DLB or PD.[5][7][8] Other symptoms of the specific synucleinopathy usually manifest within 15 years of the diagnosis of RBD,[9] but may emerge up to 50 years after RBD diagnosis.[5]

Alpha-synuclein deposits can affect the cardiac muscle and blood vessels.[10] Almost all people with synucleinopathies have cardiovascular dysfunction, although most are asymptomatic.[10]

From chewing to defecation, alpha-synuclein deposits affect every level of gastrointestinal function. Symptoms include upper gastrointestinal tract dysfunction such as delayed gastric emptying or lower gastrointestinal dysfunction, such as constipation and prolonged stool transit time.[10]

Urinary retention, waking at night to urinate, increased urinary frequency and urgency, and over- or underactive bladder are common in people with synucleinopathies.[10] Sexual dysfunction usually appears early in synucleinopathies, and may include erectile dysfunction, and difficulties achieving orgasm or ejaculating.[10]

Mechanism

[edit]

The pathological aggregation of alpha-synuclein plays a key role in neurodegenerative disease.[11] The misfolding and aggregation of alpha-synuclein form toxic fibrils, which in turn form pathological inclusions, such as Lewy bodies.[12] These protein deposits are a hallmark of synucleinopathies, and may interrupt crucial neuronal processes, such as functions of synaptic vesicles, leading to neuronal death.[11] While PD and DLB are characterized by neuronal aggregates of alpha-synuclein, MSA is characterized by glial aggregates, featuring glial cytoplasmic inclusions rather than Lewy bodies.[13]

Alpha-synuclein is encoded by the SNCA gene, and rare mutations in this gene can lead to dysfunctions of the protein structure.[14] Post-translational modifications are also implicated in the aggregation of alpha-synuclein, mostly occurring in the C-terminus. Phosphorylation, acetylation, ubiquitination, oxidation, and other modifications alter the structure and charge of alpha-synuclein, which can in turn lead to the formation of Lewy bodies.[15]

Alpha-synuclein has a prion-like molecular spread and is suggested to be released through rare exocytosis pathways.[15] This release with exosomes on their way to degradation in lysosomes suggests this process may be calcium-dependent, and therefore suggests propagation of misfolded alpha-synuclein between neurons synaptically connected.[15] Neuronal death caused by aggregated alpha-synuclein may also further accelerate the formation of these toxic aggregates, which can then trigger a selective progression of neuronal death through impairment of the mitochondria, alteration of calcium homeostasis, and lysosomal dysfunction.[14][16]

Early synaptic and plastic alterations mediated by alpha-synuclein, as well as the mechanisms of inflammation and synaptic dysfunction that occurs before neurodegeneration, are of key interest for investigating possible therapies for synucleinpathies.[16]

Diagnosis

[edit]

Differential diagnosis

[edit]

Persons with PD are typically less caught up in their visual hallucinations than those with DLB.[17] There is a lower incidence of tremor at rest in DLB than in PD, and signs of parkinsonism in DLB are more symmetrical.[6] In MSA, autonomic dysfunction appears earlier and is more severe, and is accompanied by uncoordinated movements, while visual hallucinations and fluctuating cognition are less common than in DLB.[18] Urinary difficulties are one of the earliest symptoms with MSA, and are often severe.[10]

Management

[edit]

As of 2016, there are no medications that stop or improve the progression of synucleinopathies; treatments are limited to managing symptoms.[19] Symptomatic therapies include medications for motor symptoms, treatments for autonomic dysfunction, and management of sleep or cognitive problems.[10] Non-pharmacological approaches such as physical therapy, occupational therapy, and speech therapy are also commonly used.[10][20]

Since alpha-synuclein is involved in the synucleinopathies, many potential disease-modifying treatments target this protein and its role in early inflammation and synaptic dysfunction.[19]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Synucleinopathy

View on Grokipedia
from Grokipedia
Synucleinopathies are a heterogeneous group of progressive neurodegenerative disorders characterized by the intracellular accumulation of misfolded protein, which forms pathological aggregates such as Lewy bodies in neurons and glial cytoplasmic inclusions in glial cells. These aggregates disrupt cellular function, leading to neuronal loss and dysfunction primarily in the . The major synucleinopathies include (PD), (DLB), and (MSA), each distinguished by distinct patterns of alpha-synuclein pathology and clinical presentations. In PD, the most common synucleinopathy, aggregates predominantly as Lewy bodies in the , resulting in loss and motor symptoms such as bradykinesia, rigidity, and resting ; up to 80% of patients eventually develop as (). DLB features early cognitive decline with fluctuating attention, visual hallucinations, and , accompanied by widespread cortical Lewy bodies that overlap clinically with but prioritize dementia onset. MSA, in contrast, involves glial cytoplasmic inclusions rich in , leading to degeneration in multiple systems and symptoms including autonomic failure (e.g., ), cerebellar (MSA-C subtype), or predominant (MSA-P subtype), with a more rapid progression and average survival of 6-10 years. The pathophysiology of synucleinopathies centers on the prion-like propagation of aggregates, which spread along neural pathways, exacerbated by genetic factors such as mutations or multiplications in the SNCA gene (encoding ) and mitochondrial dysfunction. Epidemiologically, PD affects approximately 1-2% of individuals over age 60, making it the most prevalent, while DLB and MSA are rarer, with annual incidences of about 3-5 per 100,000 and 0.6-0.7 per 100,000, respectively. Diagnosis increasingly relies on molecular biomarkers, such as (RT-QuIC) assays detecting seeding in or skin biopsies, achieving sensitivities up to 95% in PD. Emerging therapies target clearance through immunotherapies (e.g., monoclonal antibodies like prasinezumab) and gene-silencing approaches, with ongoing clinical trials as of 2025 showing potential to modify disease progression.

Definition and Classification

Definition

Synucleinopathies are a group of progressive neurodegenerative diseases characterized by the abnormal intracellular accumulation of misfolded protein in neurons and of the . This accumulation leads to the formation of pathological inclusions that contribute to neuronal dysfunction and degeneration. The pathological significance of was first recognized in the late 1990s, when it was identified as the primary component of Lewy bodies in brains. This discovery built on earlier descriptions of Lewy bodies dating back to 1912, but the link to established a unifying framework. The term "synucleinopathy" was introduced in 1998 to describe disorders sharing this pathology, encompassing conditions beyond . A key pathological hallmark of synucleinopathies is the presence of Lewy bodies and Lewy neurites, which are intraneuronal inclusions composed primarily of aggregated filaments. These structures are and ubiquitinated, distinguishing them from other cellular debris in affected brain regions. Synucleinopathies are distinguished from other proteinopathies, such as tauopathies like , by their specific reliance on alpha-synuclein aggregation rather than or beta-amyloid pathology, although co-occurrence can happen in some cases. Examples of synucleinopathies include and .

Classification and Types

Synucleinopathies are classified as a group of neurodegenerative disorders characterized by the abnormal accumulation of protein, primarily including (PD), (DLB), (MSA), and (PAF). These conditions are distinguished by their predominant clinical presentations and pathological features, such as neuronal or glial inclusions. Parkinson's disease features progressive nigrostriatal degeneration leading to dopaminergic neuron loss in the substantia nigra, accompanied by intraneuronal Lewy bodies composed of alpha-synuclein aggregates. Dementia with Lewy bodies is marked by early and prominent cognitive impairment, often with visuospatial deficits and fluctuating attention, alongside cortical Lewy body pathology. Multiple system atrophy involves glial cytoplasmic inclusions of alpha-synuclein in oligodendrocytes, resulting in widespread neurodegeneration and early autonomic failure, including orthostatic hypotension and urinary dysfunction. Pure autonomic failure represents a more restricted form, primarily affecting the peripheral autonomic nervous system with alpha-synuclein deposits in autonomic ganglia, leading to isolated orthostatic hypotension without central motor involvement. PD and DLB exist on a clinical continuum, differentiated by the timing of symptom onset; the "one-year rule" posits that if precedes or occurs within one year of parkinsonian motor symptoms, the is DLB, whereas later cognitive decline indicates PD with . This arbitrary threshold aids clinical distinction but reflects overlapping pathology. Rare variants of synucleinopathy occur in pediatric neuroaxonal dystrophies, such as infantile neuroaxonal dystrophy and type 1, where alpha-synuclein-positive inclusions appear in axonal spheroids and dystrophic neurites. Pathological staging in synucleinopathies, particularly PD, follows the Braak scheme, which delineates progression from early inclusions in the dorsal motor nucleus of the vagus (stage 1) and lower brainstem through midbrain involvement (stage 3-4, affecting the ) to limbic and neocortical regions (stages 5-6). This model highlights a predictable caudorostral spread of pathology. As of 2024, emerging biological research criteria, such as the SynNeurGe framework and an integrated staging system for neuronal α-synuclein disease, incorporate detection of pathological α-synuclein (e.g., via biomarkers in or skin) to enable earlier classification and staging in research settings, regardless of clinical symptoms.

Pathophysiology

Role of Alpha-Synuclein

Alpha-synuclein is a 140-amino-acid protein encoded by the SNCA gene located on chromosome 4q22.1, where it is abundantly expressed in neurons of the central nervous system. Under physiological conditions, alpha-synuclein primarily localizes to presynaptic terminals, where it plays key roles in synaptic function, including the regulation of vesicle trafficking and neurotransmitter release. It interacts with synaptic vesicles to modulate their clustering, docking, and recycling, facilitating efficient synaptic vesicle exocytosis through promotion of SNARE-complex assembly. Additionally, alpha-synuclein helps maintain dopamine homeostasis by influencing dopamine release and uptake in presynaptic neurons, with studies in knockout models showing increased striatal dopamine levels upon its absence. Beyond synaptic roles, it contributes to mitochondrial protection by binding to mitochondrial membranes, promoting fission, and supporting lipid metabolism and electron transport chain activity. In pathological contexts, undergoes conformational changes from its natively unfolded monomeric state to oligomeric and forms, leading to the formation of insoluble amyloid that characterize synucleinopathies. These shifts are exacerbated by post-translational modifications, particularly at serine 129 (Ser129), which constitutes approximately 90% of in pathological inclusions and accelerates formation by altering solubility and promoting aggregation-prone structures. also briefly interacts with other proteins such as , potentially influencing stability and aggregation propensity in overlapping neurodegenerative pathways. Alpha-synuclein is predominantly distributed in neurons, concentrating at presynaptic terminals, though in (MSA), it abnormally accumulates in glial cells, particularly oligodendroglia, forming glial cytoplasmic inclusions. Genetic variations in SNCA strongly link to synucleinopathies, with missense mutations such as A53T and A30P causing autosomal dominant familial (PD) by enhancing protein misfolding and aggregation. Furthermore, SNCA gene duplications and triplications increase expression levels, leading to earlier-onset PD with more severe pathology, as dosage effects drive overexpression and toxicity.

Aggregation and Propagation Mechanisms

The aggregation of follows a nucleation-polymerization model, in which soluble monomers initially form transient oligomers that act as nuclei for further assembly into protofibrils and eventually mature into beta-sheet-rich amyloid fibrils exhibiting sigmoidal kinetics. This process is accelerated by environmental factors such as , which promotes the formation of that stabilize oligomeric intermediates, and metal ions like iron and , which bind to and induce conformational changes favoring fibrillization. For instance, iron ions facilitate the oxidation of methionine residues, enhancing aggregation propensity and contributing to the formation of toxic species. Alpha-synuclein aggregates exhibit prion-like propagation, spreading from cell to cell through mechanisms including exosome release, tunneling nanotubes, and , allowing misfolded conformers to template the aggregation of native protein in recipient neurons. This intercellular transmission aligns with the Braak hypothesis, which posits an ascending progression of starting in the and dorsal motor nucleus of the vagus in the , subsequently advancing to midbrain structures like the and eventually the . Experimental evidence from animal models supports this pattern, demonstrating that injected fibrillar seeds induce widespread Lewy body-like inclusions following predictable neuroanatomical routes. The toxicity of primarily arises from soluble oligomers rather than mature , which impair mitochondrial function by inhibiting complex I activity and disrupting calcium , leading to energy deficits and oxidative damage. Oligomers also trigger stress through accumulation within the ER lumen, activating the unfolded protein response and promoting via pathways like CHOP induction. Additional mechanisms include synaptic disruption by binding to vesicle membranes and interfering with release, as well as mediated by microglial activation in response to extracellular oligomers, which amplifies neuronal damage through release. Recent studies up to 2025 have highlighted cross-seeding interactions between and , where fibrils promote tau aggregation in mixed pathologies, exacerbating neurodegeneration in conditions like with . Strain-specific conformers have been shown to induce distinct tau fibril structures, influencing propagation efficiency and pathology severity. Furthermore, systemic factors such as gut contribute to seeding, with microbial metabolites like imidazole propionate from elevating levels in the and facilitating brain propagation via the . Overexpression of in mouse models has been linked to reduced gut microbial diversity, suggesting a bidirectional gut-brain axis influence on aggregation initiation.

Epidemiology

Prevalence and Incidence

Synucleinopathies encompass a group of neurodegenerative disorders characterized by aggregation, with (PD) being the most prevalent form. Globally, PD affects approximately 10-12 million individuals, representing about 1% of people over 60 years and up to 4% over 80 years. (DLB) has a lower , accounting for 4-16% of cases and affecting roughly 1-5 per 1,000 individuals over 65 years. (MSA), a rarer synucleinopathy, has a of 2-5 per 100,000 population. Incidence rates for synucleinopathies also vary by type, with PD showing the highest burden. The annual global incidence of PD is estimated at 8-18 per 100,000, rising to 15.6 per age-standardized in 2021, driven by population aging. For DLB, incidence is approximately 3.5 per 100,000 person-years, while MSA incidence ranges from 0.6-0.7 per 100,000 annually. Projections indicate a substantial increase in PD cases, with estimates of approximately 20 million worldwide by 2040 due to demographic shifts. Geographic variations highlight higher PD incidence in industrialized regions such as and compared to sub-Saharan Africa and parts of Asia, potentially linked to environmental exposures like pesticides. Age distribution shows onset typically after age 50, with rates escalating sharply thereafter; for instance, PD prevalence peaks in those over 80. Sex differences reveal a slight male predominance, with men 1.5 times more likely to develop PD and similar trends in MSA, though DLB shows more balanced distribution.

Risk Factors and Genetics

Synucleinopathies, including (PD), (DLB), and (MSA), have a multifactorial involving genetic predispositions that account for a subset of cases. Mutations and multiplications in the SNCA gene, which encodes , are implicated in approximately 1-2% of autosomal dominant familial PD cases, often leading to early-onset disease with variable depending on whether it involves duplications or triplications. Genome-wide association studies (GWAS) have identified additional risk loci, such as variants in and GBA genes, which confer susceptibility to sporadic PD; for instance, GBA variants represent the most common genetic risk factor overall and are particularly prevalent in Ashkenazi Jewish populations, where they occur in up to 15-20% of PD cases compared to 5-10% in non-Jewish cohorts. These genetic factors highlight the role of dysregulation and lysosomal dysfunction in disease initiation, though they explain only a minority of cases, underscoring the importance of non-genetic contributors. Among non-genetic risk factors, age is the strongest, with PD rarely occurring before 60 years and incidence increasing exponentially thereafter. Environmental exposures significantly modulate synucleinopathy , with occupational or residential contact to pesticides such as and consistently linked to increased PD incidence through mechanisms involving and mitochondrial impairment (pooled OR 1.76). Additional environmental toxins, including heavy metals (e.g., lead, manganese), industrial solvents, and air pollution, have been associated with elevated PD risk via similar neurotoxic pathways. Similarly, exposure to the toxin , historically observed in drug users, induces by selectively destroying neurons, serving as a model for environmental triggers in synucleinopathies. Head trauma, particularly repeated concussions from or contact sports, elevates by promoting and aggregation, with epidemiological data showing a dose-dependent association (pooled OR 1.57). Rural living (pooled OR 1.32) and drinking well water (pooled OR 1.34) are also linked to increased risk, likely due to higher exposure to agricultural chemicals and contaminants. Emerging evidence suggests possible associations with dairy consumption (pooled RR 1.40 for dairy foods) and infections or chronic inflammation, which may contribute to pathology through immune activation and gut-brain axis disruptions (e.g., H. pylori infection, pooled OR 1.65). In contrast, certain factors appear protective: consumption from or tea reduces PD by up to 25-30% in meta-analyses, potentially via antagonism; , attributed to nicotine's neuroprotective effects, lowers by 40-50% among ever-smokers; and regular , such as , is associated with a 30-40% reduction through enhanced neurotrophic support and reduced inflammation. Beyond direct genetic and environmental influences, emerging contributors include gut dysbiosis, characterized by reduced microbial diversity and altered short-chain fatty acid production, which may trigger early misfolding in the and facilitate prion-like propagation to the via the . In DLB specifically, vascular risk factors such as , , and contribute to disease progression and cognitive decline, often coexisting with pathology and exacerbating cerebral hypoperfusion. Gene-environment interactions further amplify vulnerability; for example, GBA mutation carriers exposed to pesticides exhibit a markedly higher PD risk, with odds ratios up to 3-4 times greater than non-exposed carriers, suggesting synergistic effects on lysosomal function and clearance. These interactions emphasize the need for personalized in at-risk populations.

Clinical Features

Motor Symptoms

Synucleinopathies, including (PD), (MSA), and (DLB), share core motor manifestations collectively known as . These cardinal features encompass bradykinesia, characterized by slowness and poverty of movement; rigidity, manifesting as increased muscle tone leading to stiffness; resting tremor, typically a 4-6 Hz pill-rolling in PD that diminishes with voluntary action; and postural instability, which involves impaired balance and a tendency toward falls, particularly prominent in MSA where it often emerges early and severely. Disease-specific variations distinguish these conditions. In PD, symptoms typically onset asymmetrically, with one side of the body affected more than the other, and resting is a prominent early feature in about 70% of cases. In contrast, MSA presents with a symmetric akinetic-rigid , featuring bradykinesia and rigidity but minimal resting , often accompanied by a jerky postural ; postural instability is especially severe, with moderate to severe impairment within three years of motor onset. DLB exhibits symmetric dominated by bradykinesia and rigidity, with resting present in fewer than 50% of patients and generally less pronounced than in PD. Progression patterns differ markedly across synucleinopathies, influencing treatment responses and clinical trajectories. In PD, motor symptoms respond well to levodopa initially, with sustained benefits for bradykinesia and rigidity, though and postural instability show variable improvement; gait freezing—sudden involuntary arrests during walking—and falls become prominent in advanced stages, often after 8-10 years from . MSA demonstrates poor levodopa responsiveness, with rapid deterioration leading to early gait freezing, frequent falls, and need for gait aids within three years. In DLB, levodopa provides moderate relief for parkinsonian features, but progression includes early postural instability and falls, exacerbating motor disability. The functional impact of these motor symptoms profoundly affects daily life, marking key milestones. In PD, progression to severe impairment often culminates in recurrent falls and dependence for a subset of patients within 10-20 years of onset, alongside reduced arm swing, stooped posture, and loss of independence in mobility. MSA leads to faster functional decline, with use typically required within 5-7 years due to profound postural and falls. DLB's motor burden contributes to earlier mobility limitations, though less severe than in MSA, often intersecting with broader impairments.

Non-Motor Symptoms

Non-motor symptoms in synucleinopathies, such as (PD), (DLB), (MSA), and (PAF), reflect the widespread involvement of pathology beyond motor systems, affecting cognition, autonomic function, mood, sleep, and sensory processing. These symptoms often emerge early, sometimes preceding motor by years, and contribute significantly to reduced . Cognitive impairments are prominent across synucleinopathies, with being a core feature in PD, affecting up to 93% of patients due to disruptions in frontostriatal circuits. In early PD, (MCI) occurs in 15-40% of cases, characterized by deficits in , planning, and set-shifting, which may progress to in later stages. Visual hallucinations, a hallmark of DLB, affect 60-80% of patients and are typically vivid, recurrent, and feature animate objects like people or animals, linked to and visual processing deficits. Autonomic dysfunction manifests early and variably, with causing and syncope in MSA and PAF, often as an initial symptom due to central and peripheral accumulation in autonomic pathways. arises from delayed gastric emptying and colonic issues, prevalent in PD and MSA, while urinary dysfunction, including incontinence and retention, is particularly severe in MSA, reflecting involvement of the . These symptoms highlight the multisystem nature of synucleinopathies, with autonomic failure distinguishing MSA and PAF from PD. Psychiatric and sleep disturbances further underscore non-motor burden, with depression affecting approximately 50% of PD patients, often presenting as , , and anxiety tied to and serotonergic imbalances. REM sleep behavior disorder (RBD), involving dream enactment and loss of muscle atonia during REM sleep, serves as a prodromal marker, with up to 80% of idiopathic cases progressing to a synucleinopathy like PD or DLB over 10-15 years. , a pervasive issue, compounds these, reducing daily functioning. Sensory symptoms include olfactory loss (), occurring in about 90% of PD patients and often predating motor signs by years, due to deposition in the and tract. , manifesting as musculoskeletal aches or neuropathic discomfort, and are also common, affecting over half of patients in advanced stages and linked to central and non-dopaminergic pathways. In the prodromal phase, non-motor signs like and can appear 10-20 years before motor onset, signaling early spread from the brainstem and . Recognition of these, such as constipation in 20-30% of at-risk individuals, aids in identifying preclinical synucleinopathy, emphasizing the need for longitudinal monitoring.

Diagnosis

Clinical Evaluation

Clinical evaluation of synucleinopathies begins with a detailed taking to identify symptom onset, progression, and potential prodromal features. Patients are queried about the initial motor symptoms such as or bradykinesia, as well as non-motor prodromal signs including rapid eye movement sleep behavior disorder (), olfactory dysfunction, and constipation, which can precede overt neurodegeneration by years. Family history is scrutinized for hereditary patterns, particularly in cases suggestive of genetic forms like those linked to SNCA mutations. The UK Parkinson's Disease Society Brain Bank criteria, established in 1988, guide the assessment for Parkinson's disease (PD) by requiring bradykinesia plus at least one of unilateral tremor, rigidity, or postural instability, while excluding alternative causes. Physical examination focuses on neurological assessment to confirm core features of the suspected synucleinopathy subtype. In PD, clinicians evaluate for bradykinesia through tasks like finger tapping or hand pronation-supination, alongside rigidity assessed via passive joint movement and resting tremor observed during relaxation. For (DLB), cognitive screening using tools like the Mini-Mental State Examination (MMSE) or (MoCA) helps detect early visuospatial and executive dysfunction. In (MSA), examination emphasizes , , and early autonomic features such as . Diagnostic criteria provide structured frameworks for probable or definite diagnosis across synucleinopathies. The Movement Disorder Society (MDS) criteria for PD, published in 2015, classify cases as clinically established PD based on (bradykinesia with rigidity or rest tremor) in the absence of red flags like rapid progression or poor levodopa response, incorporating supportive elements like . The 2017 DLB consortium criteria require dementia with core features such as fluctuating cognition, visual hallucinations, , or , plus supportive biomarkers for increased diagnostic certainty. MSA criteria, revised in 2022 by the Movement Disorder Society (building on the 2008 Gilman criteria), include categories for clinically established, probable, and possible prodromal MSA, mandating autonomic failure (e.g., or ) alongside or cerebellar syndrome, with poor levodopa responsiveness as a key discriminator and supportive biomarkers enhancing certainty. A multidisciplinary approach enhances accuracy in subtype differentiation, involving neurologists for motor evaluation, neuropsychologists for cognitive and behavioral profiling, and sleep specialists for RBD confirmation via polysomnography history. This collaborative assessment refines the clinical , distinguishing PD from atypical parkinsonisms like DLB or MSA based on symptom constellation and progression patterns.

Imaging and Biomarkers

Neuro plays a crucial role in the and differentiation of synucleinopathies by visualizing deficits and structural changes associated with pathology. Dopamine transporter (DaT) single-photon emission computed tomography (SPECT) , using tracers like 123I-ioflupane, reveals reduced striatal uptake in (PD), (DLB), and (MSA), reflecting nigrostriatal degeneration common to these conditions. In MSA, particularly the cerebellar subtype (MSA-C), (MRI) often shows the characteristic "hot cross bun" sign, a in the on axial T2-weighted images due to degeneration of pontocerebellar fibers. Emerging (PET) tracers targeting aggregates, such as [18F]ACI-12589, have demonstrated specific binding in MSA and other synucleinopathies, offering potential for direct visualization of pathological aggregates, with clinical validation advancing as of 2023-2025. Cerebrospinal fluid (CSF) biomarkers provide insights into dynamics in synucleinopathies. Total levels are typically reduced in PD and DLB, reflecting sequestration into aggregates, while oligomeric forms are elevated across synucleinopathies. has emerged as a minimally invasive method to detect phosphorylated deposits using seeded (RT-QuIC) assays, achieving sensitivities exceeding 90% for PD and related disorders in studies up to 2024. Blood-based biomarkers offer accessible alternatives for monitoring synucleinopathies. Seed amplification assays (SAAs), including RT-QuIC variants, detect misfolded seeds in plasma with high specificity for PD, DLB, and MSA, enabling early identification of pathology. Additionally, plasma neurofilament light chain () levels serve as a marker of axonal neurodegeneration, elevated across synucleinopathies and correlating with disease progression. Recent advances in RT-QuIC assays have enabled antemortem by amplifying detectable seeding activity from CSF or other fluids, with specificities approaching 100% for distinguishing synucleinopathies from non- disorders. Gut biopsies, particularly from the , reveal enteric aggregates years before motor symptoms in PD, supporting the gut-brain axis hypothesis and providing a tool for prodromal detection through or seeding assays.

Differential Diagnosis

Synucleinopathies, including (PD), (DLB), and (MSA), present with overlapping parkinsonian features that necessitate differentiation from other causes of . is distinguished by its action or postural , typically bilateral and responsive to alcohol or beta-blockers, without rest , bradykinesia, or rigidity characteristic of PD. Drug-induced parkinsonism, often from antipsychotics or antiemetics, features symmetrical symptoms that resolve upon drug withdrawal, unlike the progressive course of synucleinopathies, and shows normal dopamine transporter imaging. Vascular parkinsonism emphasizes lower body involvement with a step-wise progression linked to cerebrovascular events, exhibiting poor levodopa response and frequent gait instability without upper limb . For DLB, key dementia mimics include (AD), which primarily manifests with early memory loss and / biomarkers on analysis or imaging, contrasting with DLB's fluctuating cognition, visual hallucinations, and prominent . (FTD) is differentiated by early behavioral changes, language impairments, and relative sparing of memory, with variable but less autonomic dysfunction than in DLB. In MSA, alternatives such as (PSP) feature symmetrical axial rigidity, early falls, and vertical gaze palsy, with minimal autonomic involvement and poor levodopa response, unlike MSA's cerebellar or autonomic predominance. presents asymmetrically with rigidity, , , , and alien limb phenomena, also levodopa-resistant but without MSA's early or urinary dysfunction. Critical discriminators across synucleinopathies include levodopa responsiveness, which is robust in PD but poor or absent in MSA, PSP, and . Autonomic features like and genitourinary dysfunction are prominent in MSA and present in PD/DLB but typically absent in PSP and vascular parkinsonism. Imaging findings, such as dopamine transporter scans or MRI patterns, further aid differentiation but are interpreted in the context of clinical features.

Management

Symptomatic Treatments

Symptomatic treatments for synucleinopathies focus on alleviating motor and non-motor manifestations in disorders such as (PD), (DLB), and (MSA), using pharmacological and non-pharmacological approaches tailored to individual symptoms. These interventions provide relief without addressing the underlying pathology, emphasizing a multidisciplinary strategy to enhance . Management of motor symptoms, predominant in PD and MSA, centers on dopaminergic therapies. In PD, levodopa/carbidopa is the most effective agent for bradykinesia and rigidity, typically initiated at low doses (e.g., 25/100 mg three times daily) and titrated gradually to optimize efficacy while reducing adverse effects. Dopamine agonists like serve as monotherapy in early stages or adjuncts later, offering substantial motor benefits comparable to levodopa in initial therapy. Monoamine oxidase-B (MAO-B) inhibitors, such as , provide mild symptomatic improvement and extend "on" time in fluctuating patients. For advanced PD with refractory motor fluctuations, (DBS) of the subthalamic nucleus or interna reduces off-time and dyskinesias, sustaining benefits for up to 10 years. In MSA, levodopa responsiveness is limited but may yield partial parkinsonian symptom relief at doses up to 1000 mg/day. Non-motor symptoms require targeted interventions across synucleinopathies. In DLB, inhibitors like improve cognition and reduce hallucinations, with patches (up to 13.3 mg/24 hours) preferred to minimize gastrointestinal side effects; these agents also enhance neuropsychiatric profiles, including delusions and . Depression, common in PD and other synucleinopathies, responds well to selective serotonin reuptake inhibitors (SSRIs) such as sertraline or . For in MSA, (2.5–30 mg/day in divided doses) acts as a peripheral alpha-1 to elevate standing blood pressure and mitigate syncope risk. Supportive non-pharmacological therapies complement by addressing functional impairments. Physical and enhance gait stability, balance, and , with programs like dance or gym-based exercises recommended early in PD to prevent . Speech-language therapy, including techniques like the Lee Silverman Voice Treatment, improves hypophonia and , reducing aspiration risk through swallowing exercises and dietary modifications such as thickened liquids. Long-term use of these treatments carries notable risks. Chronic levodopa exposure in PD often leads to levodopa-induced dyskinesias, affecting up to 80% of patients after 5–10 years, necessitating dose adjustments or adjuncts like . agonists increase the incidence of hallucinations and impulse control disorders, such as pathological , particularly in younger patients. In MSA, midodrine may exacerbate supine hypertension, requiring monitoring. Overall, therapy must balance symptom control with mitigation through regular multidisciplinary monitoring.

Disease-Modifying Approaches

Disease-modifying approaches for synucleinopathies aim to target the underlying pathology rather than merely alleviating symptoms, with most therapies remaining in preclinical or early clinical stages. Immunotherapies, such as the prasinezumab, which selectively binds aggregated forms of , have shown promise in slowing motor progression in early (PD). In the phase 2b PADOVA trial completed in 2024, prasinezumab reduced the risk of confirmed motor progression with a of 0.84 (95% CI 0.69-1.01, p=0.0657), particularly in treatment-naïve patients, though it missed the primary endpoint overall. This led to advancement into phase 3 trials in 2025. Antisense (ASOs) represent another strategy to reduce SNCA gene expression and levels. Preclinical studies in rodent models of PD demonstrated that ASOs targeting SNCA transcripts lowered production and slowed pathological deposition and spread. Clinical progress includes the phase 1 trial of ION464 for (MSA), an ASO designed to inhibit production, which reported and tolerability in 2024 with ongoing dosing. Similarly, the first-in-human study of ALN-SNCA for early PD began in 2025, focusing on reducing expression. Neuroprotective strategies seek to preserve neuronal function by addressing mitochondrial dysfunction and other downstream effects of aggregation. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as , have been investigated for their potential to slow PD progression through anti-inflammatory and neurotrophic effects. The phase 3 , reported in 2025, evaluated weekly over 96 weeks but found no significant difference from in motor progression as measured by the Movement Disorder Society-Unified Rating Scale (MDS-UPDRS) part III, indicating limited clinical impact despite prior phase 2 signals. (UDCA), a that supports mitochondrial function, improved energy production in PD patient-derived fibroblasts and protected against toxicity in preclinical models. The phase 2 UP Study in 2023 confirmed UDCA's safety and tolerability in early PD at high doses (30 mg/kg/day), with evidence of enhanced mitochondrial respiration in peripheral blood cells, warranting larger efficacy trials. Gene therapy approaches focus on directly modulating genetic contributors to synucleinopathy. (AAV)-mediated SNCA silencing vectors, such as those using (shRNA) or microRNA-embedded constructs, have demonstrated knockdown in preclinical models, ameliorating behavioral deficits and preventing pathological spreading in and PD models, though some vectors showed toxicity. For cases involving GBA mutations, which increase synucleinopathy risk, inhibitors target convergent pathways where LRRK2 hyperactivity exacerbates deficiency and accumulation. Denali Therapeutics' DNL151 (BIIB122), a selective LRRK2 inhibitor, advanced to phase 2b trials in 2023 for PD patients with or without LRRK2 mutations, showing target engagement and safety. As of 2025, several updates highlight advancing investigational therapies. Ongoing phase 2 trials for vaccines, such as AC Immune's VacSYn (ACI-7104.056) targeting misfolded aggregates to induce immune clearance, continue with interim data showing immune responses in early PD patients, though full efficacy results remain pending. transplants for replacement, using human embryonic or induced pluripotent stem cell-derived progenitors, reported safety and preliminary motor improvements in phase 1/2 trials; for instance, a Japanese trial of allogeneic iPSC-derived cells demonstrated survival, production, and symptom reduction without tumors at 18 months post-transplant. Gut-brain axis modulators, including and dietary interventions to alter composition, are emerging as adjuncts to mitigate propagation from the gut, with preclinical evidence showing reduced and aggregation in synucleinopathy models.

Prognosis

Disease Progression

Synucleinopathies exhibit variable progression rates across subtypes, with (PD) typically following a slower course compared to (MSA) and (DLB). In PD, disease advancement is often assessed using the , which categorizes stages from 1 (unilateral involvement with minimal or no functional impairment) to 5 (wheelchair-bound or bedridden with significant disability). Progression through these stages generally spans 10-20 years from diagnosis to severe disability, though individual timelines vary based on factors such as age at onset and treatment adherence. In contrast, MSA progresses more rapidly, with a median survival of 6-10 years from symptom onset, often leading to profound disability within this timeframe due to early autonomic dysfunction and multisystem involvement. is characterized by rapid progression, with early and severe cognitive decline alongside parkinsonism, visual hallucinations, and fluctuating cognition; median survival is 5-7 years from diagnosis, shorter than PD but variable based on age and comorbidities. Several factors influence the rate of progression in synucleinopathies. In PD, younger age at onset is associated with a slower disease course, potentially allowing for extended periods of milder symptoms before advancing to higher Hoehn and Yahr stages. Conversely, MSA demonstrates accelerated decline, primarily driven by autonomic failure, which contributes to early , urinary dysfunction, and respiratory complications that hasten functional deterioration. DLB progression is often nonlinear, with abrupt worsening due to sensitivity to neuroleptics and infections. Genetic and environmental modifiers, such as GBA1 mutations, may further modulate progression speed across synucleinopathies, though their impact varies by subtype. Key milestones in synucleinopathy progression include the emergence of cognitive and motor complications. In PD, approximately 30-50% of patients transition to within 10 years of diagnosis, marking a critical shift toward greater dependency. Cumulative motor complications, such as dyskinesias and fluctuations, affect up to 50% of PD patients after 5-10 years of levodopa , compounding mobility challenges and reducing . In DLB, cognitive fluctuations and hallucinations often intensify early, leading to increased caregiver needs within 2-3 years. Survival outcomes differ markedly: with modern treatments, PD life expectancy approaches that of the general population, particularly for those diagnosed before age 70, while MSA carries a median post-diagnosis survival of 7-9 years and DLB 5-7 years.

Complications and Outcomes

Synucleinopathies, including (PD), (DLB), and (MSA), are marked by several debilitating complications that drive morbidity and mortality. stands out as the leading cause of death in PD, stemming from and silent aspiration due to impaired swallowing coordination. Falls and associated fractures frequently arise from postural instability and gait freezing, increasing hospitalization risk and accelerating disability. In DLB, advanced manifests as severe , visual hallucinations, and fluctuating alertness, heightening vulnerability to infections and care challenges. These complications erode , with depression affecting up to 50% of patients across synucleinopathies and elevating risk, particularly in early to mid-stages of PD and DLB. burden intensifies as disease advances, with family members facing physical exhaustion from mobility assistance and emotional strain from behavioral symptoms, often leading to their own health decline. plays a crucial role in mitigating these impacts by addressing pain, through swallowing therapy, and end-of-life planning to enhance patient comfort and reduce caregiver stress. Long-term outcomes reflect progressive functional decline, with approximately 80% of PD patients developing motor complications like dyskinesias and "off" periods by 10 years, often resulting in loss of and need for daily assistance. Hospice utilization remains limited, with only about 4% of PD patients in the United States receiving home-based care at end of life, despite preferences for dying at home. As of 2025, emerging evidence underscores the benefits of early intervention in prodromal synucleinopathies to delay complications such as falls and through targeted therapies and lifestyle modifications. Telemedicine has proven effective for remote outcomes monitoring, improving access to care for non-motor symptoms and reducing complication risks via virtual assessments.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC8684287/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC11947388/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC5345650/
  4. https://jamanetwork.com/journals/jamaneurology/fullarticle/1738443
  5. https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-021-00501-z
  6. https://jamanetwork.com/journals/jamaneurology/fullarticle/778475
  7. https://pubmed.ncbi.nlm.nih.gov/14502652/
  8. https://www.nature.com/articles/s41419-023-05672-9
  9. https://www.nia.nih.gov/health/lewy-body-dementia/lewy-body-dementia-causes-symptoms-and-diagnosis
  10. https://www.pathologyoutlines.com/topic/cnsmultiplesystematrophy.html
  11. https://emedicine.medscape.com/article/1154583-overview
  12. https://www.mayoclinicproceedings.org/article/S0025-6196%2819%2930265-4/fulltext
  13. https://www.neurology.org/doi/10.1212/WNL.0000000000004058
  14. https://pubmed.ncbi.nlm.nih.gov/39281742/
  15. https://pubmed.ncbi.nlm.nih.gov/10604751/
  16. https://ajp.amjpathol.org/article/S0002-9440%2810%2964548-8/fulltext
  17. https://pubmed.ncbi.nlm.nih.gov/12498954/
  18. https://www.sciencedirect.com/science/article/pii/S0197458002000659
  19. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00405-2/fulltext
  20. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00406-4/fulltext
  21. https://medlineplus.gov/genetics/gene/snca/
  22. https://www.ncbi.nlm.nih.gov/gene/6622
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC3866954/
  24. https://www.sciencedirect.com/science/article/abs/pii/S0022283622003060
  25. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.00382/full
  26. https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-9-43
  27. https://pubmed.ncbi.nlm.nih.gov/11560511/
  28. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17103-1/fulltext
  29. https://pubmed.ncbi.nlm.nih.gov/15304594/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC4780632/
  31. https://www.nature.com/articles/s41598-020-73207-9
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC12034127/
  33. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.00552/full
  34. https://actaneurocomms.biomedcentral.com/articles/10.1186/2051-5960-1-2
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC3609056/
  36. https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-024-00756-2
  37. https://www.jneurosci.org/content/32/10/3301
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC4396726/
  39. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1570553/full
  40. https://pubs.acs.org/doi/10.1021/jacs.5c02811
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC12413466/
  42. https://www.nature.com/articles/s41598-024-82139-7
  43. https://www.parkinson.org/understanding-parkinsons/statistics
  44. https://www.who.int/news-room/fact-sheets/detail/parkinson-disease
  45. https://www.lbda.org/about-lbd/
  46. https://pubmed.ncbi.nlm.nih.gov/27307129/
  47. https://www.orpha.net/en/disease/detail/102
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC12035419/
  49. https://www.sciencedirect.com/science/article/pii/S0011502922001250
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC10314081/
  51. https://www.bmj.com/content/388/bmj-2024-080952
  52. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01419-8/fulltext
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC7399219/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC9416236/
  55. https://www.sciencedirect.com/science/article/abs/pii/S1769721218301241
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC8461677/
  57. https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.30067
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC10326611/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC9119911/
  60. https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-019-0165-9
  61. https://www.sciencedirect.com/science/article/pii/S0969996119303468
  62. https://academic.oup.com/aje/article/175/11/1200/139780
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC10904658/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC9124602/
  65. https://beyondpesticides.org/dailynewsblog/2020/11/pesticide-exposure-increases-the-risk-of-developing-gene-specific-and-sporadic-parkinsons-disease-incidences/
  66. https://doi.org/10.1002/mds.26424
  67. https://doi.org/10.1212/01.wnl.0000324625.00404.15
  68. https://doi.org/10.1212/WNL.0000000000004058
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC7320652/
  70. https://doi.org/10.1002/ana.25132
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC6282124/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC11311369/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC4295432/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC4194347/
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC6283803/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC5859695/
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC7745651/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC9628588/
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC5562575/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC10791917/
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC3130930/
  82. https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.29005
  83. https://pubs.rsna.org/doi/full/10.1148/rg.230133
  84. https://pubmed.ncbi.nlm.nih.gov/40117078/
  85. https://www.nature.com/articles/s41467-023-42305-3
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC11504870/
  87. https://jamanetwork.com/journals/jama/fullarticle/2816441
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC11580393/
  89. https://pubmed.ncbi.nlm.nih.gov/27292537/
  90. https://pubmed.ncbi.nlm.nih.gov/34650422/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC10313076/
  92. https://www.ncbi.nlm.nih.gov/books/NBK536715/
  93. https://www.ncbi.nlm.nih.gov/books/NBK482441/
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC9661336/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC10125958/
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC7385761/
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC9599076/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC7017451/
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC5088077/
  100. https://www.roche.com/media/releases/med-cor-2024-12-19
  101. https://www.michaeljfox.org/news/drug-potential-slow-or-stop-parkinsons-moves-next-phase-clinical-testing
  102. https://insight.jci.org/articles/view/135633
  103. https://www.neurologylive.com/view/continued-progress-phase-1-study-antisense-oligonucleotide-ion464-msa
  104. https://clinicaltrials.gov/study/NCT07216066
  105. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02808-3/fulltext
  106. https://www.sciencedirect.com/science/article/pii/S0022283618309872
  107. https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.29450
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC3105182/
  109. https://pubmed.ncbi.nlm.nih.gov/21338582/
  110. https://www.michaeljfox.org/grant/convergence-lrrk2-and-gba-pathogenesis-parkinsons-disease-supplement
  111. https://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mdc3.13619
  112. https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-06354-0
  113. https://ir.acimmune.com/news-releases/news-release-details/ac-immune-reports-further-positive-interim-results-phase-2-trial
  114. https://www.nature.com/articles/s41586-025-08700-0
  115. https://www.tandfonline.com/doi/full/10.1080/14796708.2025.2505398
  116. https://journals.lww.com/nsan/fulltext/2025/07000/gut_microbiota_modulation_with_probiotics_.1.aspx
  117. https://www.parkinson.org/understanding-parkinsons/what-is-parkinsons/stages
  118. https://www.news-medical.net/health/Parkinsons-Disease-Prognosis.aspx
  119. https://www.nature.com/articles/s41531-022-00413-9
  120. https://www.mayoclinic.org/diseases-conditions/lewy-body-dementia/symptoms-causes/syc-20352025
  121. https://academic.oup.com/brain/article/133/6/1755/353024
  122. https://www.uptodate.com/contents/multiple-system-atrophy-prognosis-and-treatment
  123. https://pmc.ncbi.nlm.nih.gov/articles/PMC7014913/
  124. https://www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia
  125. https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mdc3.14044
  126. https://www.nhs.uk/conditions/parkinsons-disease/
  127. https://pmc.ncbi.nlm.nih.gov/articles/PMC4139446/
  128. https://pmc.ncbi.nlm.nih.gov/articles/PMC6474181/
  129. https://www.ncbi.nlm.nih.gov/books/NBK585113/
  130. https://www.neurology.org/doi/abs/10.1212/WNL.0000000000208878
  131. https://www.neurology.org/doi/10.1212/CPJ.0000000000200292
  132. https://pmc.ncbi.nlm.nih.gov/articles/PMC5873561/
  133. https://pmc.ncbi.nlm.nih.gov/articles/PMC3038575/
  134. https://pmc.ncbi.nlm.nih.gov/articles/PMC7851259/
  135. https://pmc.ncbi.nlm.nih.gov/articles/PMC11129688/
  136. https://pmc.ncbi.nlm.nih.gov/articles/PMC11903018/
Add your contribution
Related Hubs
User Avatar
No comments yet.